OUTCOMES OF TREAT-AND-EXTEND USING AFLIBERCEPT IN TYPE 3 MACULAR NEOVASCULARIZATION
Treat-and-extend with aflibercept for >76 weeks improved best-corrected visual acuity and significantly reduced central retinal thickness in those with Type 3 macular neovascularization. At 76 weeks, most patients maintained a dry macula, indicating that this approach is an effective and efficient treatment strategy for Type 3 macular neovascularization.
Authors
- Han Joo Cho (ORCID: https://orcid.org/0000-0001-7336-5762)
- Sang Min Park (ORCID: https://orcid.org/0000-0002-7498-4829)
- Yeji Kim (ORCID: https://orcid.org/0000-0002-3762-5018)
- Jae Hui Kim (ORCID: https://orcid.org/0000-0001-8121-6353)
Institutions
- Kim's Eye Hospital (KR)
Publication Details
- Journal
- Retina
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1097/iae.0000000000004571
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71